Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: enzinger c. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Real-life clinical use of natalizumab and fingolimod in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T. Guger M, et al. Among authors: enzinger c. Acta Neurol Scand. 2018 Feb;137(2):181-187. doi: 10.1111/ane.12864. Epub 2017 Nov 20. Acta Neurol Scand. 2018. PMID: 29159801
Month-of-birth-effect in multiple sclerosis in Austria.
Walleczek NK, Frommlet F, Bsteh G, Eggers C, Rauschka H, Koppi S, Assar H, Ehling R, Birkl C, Salhofer-Polanyi S, Baumgartner A, Blechinger S, Buchinger D, Sellner J, Kraus J, Moser H, Mayr M, Guger M, Rathmaier S, Raber B, Liendl H, Hiller MS, Parigger S, Morgenstern G, Kempf I, Spiss HK, Meister B, Heine M, Cisar A, Bachler H, Khalil M, Fuchs S, Enzinger C, Fazekas F, Leutmezer F, Berger T, Kristoferitsch W, Aboulenein-Djamshidian F. Walleczek NK, et al. Among authors: enzinger c. Mult Scler. 2019 Dec;25(14):1870-1877. doi: 10.1177/1352458518810924. Epub 2018 Nov 22. Mult Scler. 2019. PMID: 30463473
Real-life use of oral disease-modifying treatments in Austria.
Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T; Austrian MS Treatment Registry (AMSTR). Guger M, et al. Among authors: enzinger c. Acta Neurol Scand. 2019 Jul;140(1):32-39. doi: 10.1111/ane.13097. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30958901 Free PMC article.
406 results